Evidence map›Paper›PMID 41235656›Full record

ArticleAIDS (London, England)2025

Emerging patterns in HIV integrase resistance.

Margarida Veloso, Marta Ribeiro, Joaquim Cabanas, Fátima Gonçalves, Sandra Fernandes, Isabel Diogo, Inês Costa, Victor Pimentel, Marta Pingarilho, Ana Abecasis and 1 more

Abstract read
In one paragraph

Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Margarida VelosoMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Marta RibeiroMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Joaquim CabanasMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Fátima GonçalvesMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Sandra FernandesMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Isabel DiogoMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Inês CostaMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.
Victor PimentelGlobal Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisbon, Portugal.
Marta PingarilhoGlobal Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisbon, Portugal.
Ana AbecasisGlobal Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisbon, Portugal.
Perpétua GomesMolecular Biology Laboratory (SPC, Unidade Local de Saúde Lisboa Ocidental-HEM), Lisbon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed integrase resistance in 837 treatment-experienced people with HIV (PWH) with virological failure (2022-2024) in Portugal. Major resistance mutations were found in 5.5%, with N155H and R263K being the most common. Resistance was more frequent in non-B subtypes and often co-occurred with resistance to other antiretroviral classes. Though prevalence remains low, the findings highlight the need for continued surveillance to inform treatment decisions, especially as integrase inhibitors like dolutegravir, bictegravir and cabotegravir become more widely used.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsHIV IntegraseHIV Integrase InhibitorsAdultFemaleGenotypeHumansMaleMiddle AgedMutationPortugalPrevalenceHIV IntegraseHIV Integrase Inhibitors

Identifiers

PMID41235656
PMCPMC12629115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.